{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T10:16:33Z","timestamp":1787912193569,"version":"build-2784847793"},"reference-count":34,"publisher":"BMJ","issue":"5","funder":[{"name":"Laboratorio Franco Colombiano LAFRANCOL S.A.S -Abbott Colombia Affilliate","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Support Palliat Care"],"accepted":{"date-parts":[[2025,10,23]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare the incidence of febrile neutropenia (FN) and chemotherapy delays (CD) due to neutropenia in chemotherapy cycles in which pegfilgrastim (PGF) was administered on the same day (D0) vs the following day (D+1), as treatment for solid tumours.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study was conducted using the number of chemotherapy cycles with PGF administration as the unit of analysis. PGF administration on D0 was compared with administration on D+1. The incidence of FN and CD was calculated for the entire cohort and for subgroups. Relative risk (RR) between groups was assessed, a p value &lt;0.05 considered statistically significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1091 cycles with PGF administration on D0 were compared with 1089 cycles on D+1. The incidence of FN was 1.6% in D0 and 0.5% in D+1 (RR=3.4; p=0.02), and CD was 2.2% and 2.6% in D0 and D+1, respectively (RR=0.9; p=0.67). The incidence of FN on breast cancer (BC) patients was 2.4% in D0 and 0.3% in D+1 (RR=7.0; p&lt;0.01). No significant differences were identified in the incidence of FN among other tumours (OT) (RR=1.0; p=0.68).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Higher rates of FN were observed in the overall cohort when PGF was administered on D0, largely influenced by the subgroup of BC patients. Among OT, the day of PGF administration did not impact the outcome. These findings support the administration of PGF on D+1 of chemotherapy in BC patients when FN prevention is the objective. For patients with OT, administration of PGF on D0 is considered appropriate.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/spcare-2025-005804","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:55:56Z","timestamp":1762325756000},"page":"1141-1150","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Chemotherapy-associated neutropenia with same-day versus next-day pegfilgrastim in outpatient chemotherapy: solid tumour cohort study"],"prefix":"10.1136","volume":"16","author":[{"given":"Mauricio","family":"Luj\u00e1n","sequence":"first","affiliation":[{"name":"Cl\u00ednica de Oncolog\u00eda Astorga, Medell\u00edn, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4382-6676","authenticated-orcid":false,"given":"Camila","family":"Lema","sequence":"additional","affiliation":[{"name":"Cl\u00ednica de Oncolog\u00eda Astorga, Medell\u00edn, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6035-0200","authenticated-orcid":false,"given":"Diego","family":"Mor\u00e1n","sequence":"additional","affiliation":[{"name":"Cl\u00ednica de Oncolog\u00eda Astorga, Medell\u00edn, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz E","family":"Preciado","sequence":"additional","affiliation":[{"name":"Cl\u00ednica de Oncolog\u00eda Astorga, Medell\u00edn, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7957-8770","authenticated-orcid":false,"given":"Katerin","family":"Puerta A","sequence":"additional","affiliation":[{"name":"Cl\u00ednica de Oncolog\u00eda Astorga, Medell\u00edn, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Lema","sequence":"additional","affiliation":[{"name":"Cl\u00ednica de Oncolog\u00eda Astorga, Medell\u00edn, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2552-9117","authenticated-orcid":false,"given":"Mateo","family":"Pineda \u00c1lvarez","sequence":"additional","affiliation":[{"name":"Cl\u00ednica de Oncolog\u00eda Astorga, Medell\u00edn, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"2026082802200671000_16.5.1141.1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JOP.18.00269","article-title":"Optimal Management of Neutropenic Fever in Patients With Cancer","volume":"15","author":"Zimmer","year":"2019","journal-title":"J Oncol Pract"},{"key":"2026082802200671000_16.5.1141.2","doi-asserted-by":"publisher","DOI":"10.2165\/11586040-000000000-00000"},{"key":"2026082802200671000_16.5.1141.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3488"},{"key":"2026082802200671000_16.5.1141.4","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/84.15.1201"},{"key":"2026082802200671000_16.5.1141.5","unstructured":"Williams K . NCCN released recommendations for the use of hematopoietic growth factors during the COVID-19 pandemic. FLASCO Website; 2020."},{"key":"2026082802200671000_16.5.1141.6","doi-asserted-by":"crossref","unstructured":"Griffiths EA , Alwan LM , Bachiashvili K , et al . Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic. J Natl Compr Canc Netw 2020;1\u20134. doi:10.6004\/jnccn.2020.7610","DOI":"10.6004\/jnccn.2020.7610"},{"key":"2026082802200671000_16.5.1141.7","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.e18687","article-title":"The feasibility of same day pegfilgrastim-cbqv administration in breast cancer patients receiving myelosuppressive chemotherapy regimens at a northern Virginia cancer center","volume":"39","author":"Leiva","year":"2021","journal-title":"JCO"},{"key":"2026082802200671000_16.5.1141.8","doi-asserted-by":"crossref","first-page":"10112","DOI":"10.1200\/JCO.2017.35.15_suppl.10112","article-title":"Safety and efficacy of same-day administration of pegfilgrastim in patients (pts) receiving chemotherapy for gastrointestinal (GI) malignancies","volume":"35","author":"Matera","year":"2017","journal-title":"JCO"},{"key":"2026082802200671000_16.5.1141.9","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.091094"},{"key":"2026082802200671000_16.5.1141.10","unstructured":"Lawanga S , Lemeshow S . Cohort studies. In: Sample size determitation in health studies: a practical manual. World Health Organization, 1991: 12\u20133."},{"key":"2026082802200671000_16.5.1141.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923"},{"key":"2026082802200671000_16.5.1141.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.8734"},{"key":"2026082802200671000_16.5.1141.13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.0508"},{"key":"2026082802200671000_16.5.1141.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706043162302"},{"key":"2026082802200671000_16.5.1141.15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6211"},{"key":"2026082802200671000_16.5.1141.16","unstructured":"Amgen Inc . Neulasta\u00ae (pegfilgrastim) injection, for subcutaneous use: prescribing information. Amgen Website; 2025."},{"key":"2026082802200671000_16.5.1141.17","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.4764.4764","article-title":"Efficacy of Same-Day Vs. Next-Day Pegfilgrastim for the Prevention of Chemotherapy-Induced (Febrile) Neutropenia (CIN\/FN): A Meta-Analysis","volume":"126","author":"Diri","year":"2015","journal-title":"Blood"},{"key":"2026082802200671000_16.5.1141.18","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.e14510","article-title":"Outcomes of pegfilgrastim (PFG) administration on the same day vs the day after chemotherapy (CTX) in the prophylaxis of chemotherapy-induced (Febrile) neutropenia (CIN\/FN): Systematic review and meta-analysis","volume":"36","author":"AlRawashdh","year":"2018","journal-title":"JCO"},{"key":"2026082802200671000_16.5.1141.19","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-014-2270-8"},{"key":"2026082802200671000_16.5.1141.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2008.10.025"},{"key":"2026082802200671000_16.5.1141.21","doi-asserted-by":"crossref","first-page":"e429","DOI":"10.1016\/j.clgc.2016.12.003","article-title":"Safety of Same-day Pegfilgrastim Administration in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel With or Without Carboplatin","volume":"15","author":"Bilen","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"2026082802200671000_16.5.1141.22","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1200\/JCO.2020.39.28_suppl.299","article-title":"Real-world comparison of febrile neutropenia rates with same-day versus next-day administration of pegfilgrastim","volume":"39","author":"Kitchen","year":"2021","journal-title":"JCO"},{"key":"2026082802200671000_16.5.1141.23","doi-asserted-by":"publisher","DOI":"10.1080\/07357900500276899"},{"key":"2026082802200671000_16.5.1141.24","first-page":"873","article-title":"A single-arm, retrospective analysis of the incidence of febrile neutropenia using same-day versus next-day pegfilgrastim in patients with gastrointestinal cancers treated with FOLFOX or FOLFIRI","volume":"27","author":"Eckstrom","year":"2019","journal-title":"Support Care Cancer"},{"key":"2026082802200671000_16.5.1141.25","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14218"},{"key":"2026082802200671000_16.5.1141.26","first-page":"225","article-title":"Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer","volume":"7","author":"Schuman","year":"2009","journal-title":"J Support Oncol"},{"key":"2026082802200671000_16.5.1141.27","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.770067","article-title":"Analysis of the Safety of Pegfilgrastim Addition in Bleomycin, Etoposide, and Cisplatin Treatment Patients With Germ Cell Tumors","volume":"11","author":"Nakagawa","year":"2021","journal-title":"Front Oncol"},{"key":"2026082802200671000_16.5.1141.28","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.e18591","article-title":"An institutional evaluation of the safety and efficacy of same-day administration of pegfilgrastim in patients receiving chemotherapy for lung cancer","volume":"39","author":"Vraney","year":"2021","journal-title":"JCO"},{"key":"2026082802200671000_16.5.1141.29","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1080\/03007995.2018.1495621","article-title":"Risk of chemotherapy-induced febrile neutropenia with same-day versus next-day pegfilgrastim prophylaxis among patients aged \u226565 years: a retrospective evaluation using Medicare claims","volume":"34","author":"Weycker","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"2026082802200671000_16.5.1141.30","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2686-9"},{"key":"2026082802200671000_16.5.1141.31","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv619"},{"key":"2026082802200671000_16.5.1141.32","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-150989","article-title":"Meta-Analysis of Chemotherapy-Induced (Febrile) Neutropenia and Chemotherapy Disruptions Associated with Same-Day Versus Standard (24-72h) Pegfilgrastim Administration in Non-Hodgkin Lymphoma Patients","volume":"138","author":"Alrawashdh","year":"2021","journal-title":"Blood"},{"key":"2026082802200671000_16.5.1141.33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2020-002532"},{"key":"2026082802200671000_16.5.1141.34","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1177\/10781552221148116","article-title":"Efficacy of same-day versus next-day administration of pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients receiving dose-dense doxorubicin and cyclophosphamide: A retrospective multi-site analysis","volume":"29","author":"Hobbs","year":"2023","journal-title":"J Oncol Pharm Pract"}],"container-title":["BMJ Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/spcare-2025-005804","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T09:20:30Z","timestamp":1787908830000},"score":1,"resource":{"primary":{"URL":"https:\/\/spcare.bmj.com\/lookup\/doi\/10.1136\/spcare-2025-005804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,8,28]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/spcare-2025-005804"],"URL":"https:\/\/doi.org\/10.1136\/spcare-2025-005804","relation":{},"ISSN":["2045-435X","2045-4368"],"issn-type":[{"value":"2045-435X","type":"print"},{"value":"2045-4368","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]}}}